Thoracic Cancer Clinical Trials
At Orlando Health Cancer Institute, our thoracic cancer experts participate in a range of cancer research and clinical trials. Our research helps discover new, effective treatments for thoracic cancer as well as new ways to improve the quality of life for those with cancer.
If your current treatments are not effective, clinical trials can offer you more treatment options. Your clinical trial treatment options may include new chemotherapy medicines, radiation therapy techniques or other types of treatments. Your medical team will discuss with you any options you may have for treatments through clinical trials.
-
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination with Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) +
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination with Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
Protocol No: 20240178
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT07005128
Phase: III
Principal Investigators: Yuanbin Chen, MD
Eligibility Document -
Attachment Id: 24073
File Name: DeLLphi-312 Subject Eligibility _Screening Checklist 11AUG2025 v2.docx
URL:
Objective
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival.
-
A Phase IIB, Open-Label, Two-Cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Hemotherapy as Second-Line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer COPERNICUS +
A Phase IIB, Open-Label, Two-Cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Hemotherapy as Second-Line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer COPERNICUS
Protocol No: 61186372NSC2012
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT06667076
Phase: II
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 17912
File Name: Subject Eligibility _Screening Checklist_61186372NSC201 COHORT 12.docx
URL:
Objective
To study how well amivantamab works when given with lazertinib or chemotherapy in patients with a certain type of non-small cell lung cancer that has an EGFR mutation.
-
Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination with Chemoradiation Followed by Durvalumab for Locally Advanced and Unresectable Stage III Non-Small Cell Lung Cancer +
Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination with Chemoradiation Followed by Durvalumab for Locally Advanced and Unresectable Stage III Non-Small Cell Lung Cancer
Protocol No: 90301900NSC2001
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT06667908
Phase: II
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 20732
File Name: Subject Eligibility Screening Checklist Version 1.0 - 03FEB2026 - 90301900NSC2001.docx
URL:
Objective
To determine whether JNJ-90301900 as a radioenhancer added to cCRT followed by cIT can improve objective response rate in participants with locally advanced and unresectable Stage IIIA and IIIB NSCLC
-
An Interventional Phase 3, Double-Blind, Randomized Study to Evaluate Efficacy and Safety of Pf-08634404 in Combination with Chemotherapy Versus Pembrolizumab in Combination with Chemotherapy in Adult Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer +
An Interventional Phase 3, Double-Blind, Randomized Study to Evaluate Efficacy and Safety of Pf-08634404 in Combination with Chemotherapy Versus Pembrolizumab in Combination with Chemotherapy in Adult Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Protocol No: C6461001
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT07222566
Phase: III
Principal Investigators: Yuanbin Chen, MD
Objective
Evaluate whether PF-08634404 plus chemotherapy works better than Pembrolizumab plus chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer and to assess safety.
-
Perioperative Versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG +
Perioperative Versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG
Protocol No: CTIU2317-A082304-S2402
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT06632327
Phase: III
Principal Investigators: Jose Najera, MD
Objective
To compare the 3-year real-world event-free survival rate and overall survival between perioperative and adjuvant immunotherapy-based treatment for patients with resectable non-small cell lung cancer.
-
A Phase III, Randomized, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy versus Pembrolizumab Monotherapy for the First-Line Treatment of Participants with Locally-Advanced or Metastatic Non-squamous NSCLC with High PD-L1 Expression (TC greater than or equal to 50%) and without Actionable Genomic Alterations (TROPION-Lung10) +
A Phase III, Randomized, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy versus Pembrolizumab Monotherapy for the First-Line Treatment of Participants with Locally-Advanced or Metastatic Non-squamous NSCLC with High PD-L1 Expression (TC greater than or equal to 50%) and without Actionable Genomic Alterations (TROPION-Lung10)
Protocol No: D7632C00001
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT06357533
Phase: III
Principal Investigators: Yuanbin Chen, MD
Eligibility Document -
Attachment Id: 23672
File Name: Subject Eligibility Screening Checklist D7632C00001 TROPION_03APR2026.docx
URL:
Objective
Evaluate superiority of Dato-DXd + Rivegostomig vs Pembrolizumab for PFS and OS in TROP2-poiitive NSCLC
-
A Phase I/II, Open-Label Study of PD-1 Knockout Tumor-Infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer +
A Phase I/II, Open-Label Study of PD-1 Knockout Tumor-Infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer
Protocol No: IOV-GM1-201
Age Group: Adult
Disease Sites: Lung, Melanoma, Skin
NCT Id: NCT05361174
Phase: II/III
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 11553
File Name: Subject Eligibility _Baseline Checklist GM1.docx
URL:
Objective
This study is testing a new type of immune cell therapy called IOV-4001. It's being used in people with advanced melanoma or lung cancer to see if it is safe and whether it can help shrink tumors.
-
A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer +
A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer
Protocol No: MK-6070-003
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT07227597
Phase: I/II
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 22125
File Name: Subject Eligibility _Screening Checklist V1.0 22JAN2026.docx
URL:
Objective
Access safety and tolerability of MK-6070 plus I-DXd-Based regimens for first-line ES-SCLC and evaluate tumor response.
-
Phase I/II Study of mRNA-4359 Administered Alone and in Combination with Immune Checkpoint Blockade in Participants with Advanced Solid Tumors +
Phase I/II Study of mRNA-4359 Administered Alone and in Combination with Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
Protocol No: MRNA-4359-P101
Age Group: Adult
Disease Sites: Lung, Melanoma, Skin
NCT Id: NCT05533697
Phase: I/II
Principal Investigators: Yuanbin Chen, MD
Eligibility Document -
Attachment Id: 20312
File Name: Subject Eligibility _Screening Checklist Version 28JUL2025 MRNA-4359-P101.docx
URL:
Objective
The main goal of this study is to find the safest dose of the study drug and see how well it works against solid tumors. We will also check for any side effects and how the cancer responds to treatment. This helps us learn if the drug can be used safely and effectively.
-
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer +
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
Protocol No: NRG-LU008
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT05624996
Phase: III
Principal Investigators: Justin Rineer, MD
Objective
This study is comparing two types of radiation therapy, both given with chemotherapy, to see which helps patients with inoperable stage II IIIC non-small cell lung cancer live longer and stay free from cancer progression.
-
A Phase I/II, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) in Participants with Advanced Solid Tumors +
A Phase I/II, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) in Participants with Advanced Solid Tumors
Protocol No: OBX115-23-01
Age Group: Adult
Disease Sites: Multiple Myeloma
NCT Id: NCT06060613
Phase: I/II
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 22237
File Name: OBX Subject Eligibility _Baseline Checklist V6.0 20JAN2026 - .docx
URL:
Objective
This study is testing a new kind of cell therapy called OBC-115 to see if it is safe and effective in people with advanced sold tumors.
-
A Phase III Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC) +
A Phase III Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Protocol No: OHCI-LUN-26-001-IND
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT07365241
Phase: III
Principal Investigators: Yuanbin Chen, MD
Objective
This study aims to find out if the study drug ABBV-706 works better than standard treatments, topotecan, lurbinectedin, or amrubicin, by looking at how many patients tumors shrink or respond to treatment and how long patients live after starting therapy.
-
A Phase III, Multi-center, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Abenacianine (VGT-309), a Tumor-Targeted, Activatable Fluorescent Imaging Agent, to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung - VISUALIZE 2 +
A Phase III, Multi-center, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Abenacianine (VGT-309), a Tumor-Targeted, Activatable Fluorescent Imaging Agent, to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung - VISUALIZE 2
Protocol No: VGT-309-3-2025
Age Group: Adult
Disease Sites: Lung
NCT Id: NCT07499674
Phase: III
Principal Investigators: Luis Herrera, MD
Eligibility Document -
Attachment Id: 23292
File Name: VGT Eligibility.docx
URL:
Objective
Evaluate efficacy of abenacianine with NIR imaging during lung cancer surgery.
Navigate Your Health
Find a Cancer Physician
Find a Cancer Physician
Meet our doctors who specialize in the full range of cancer care. Our team of experts has experience in a variety of specialty areas. Together, we provide comprehensive evaluation, diagnosis and treatment options.
Learn More
Patient Portal
Patient Portal
If you are a patient at Orlando Health Cancer Institute, our free online patient portal provides an easy and secure way to manage your health information. Reach us from any location at a time that’s convenient for you.
Learn More
Virtual Visit
Virtual Visit
Need to talk with a doctor, but don’t want to leave your home? Try our virtual visit (telehealth) option to connect with a physician from your phone, tablet or computer.
Learn More
ER Wait Times
Thursday, May 21, 2026 10:00 PM
|
|
Wait Time | |
|---|---|---|
| Orlando Health - Health Central Hospital | Directions | 38 min |
| Orlando Health Arnold Palmer Hospital for Children | Directions | 23 min |
| Orlando Health Bayfront Hospital Emergency Room | Directions | 103 min |
| Orlando Health Dr. P. Phillips Hospital | Directions | 87 min |
| Orlando Health Emergency Room - Blue Cedar | Directions | 2 min |
| Orlando Health Emergency Room - Crossroads | Directions | 0 min |
| Orlando Health Emergency Room - Four Corners | Directions | 5 min |
| Orlando Health Emergency Room - Lake Mary | Directions | 2 min |
| Orlando Health Emergency Room - Longwood | Directions | 1 min |
| Orlando Health Emergency Room - Osceola | Directions | 28 min |
| Orlando Health Emergency Room - Pinellas Park | Directions | 0 min |
| Orlando Health Emergency Room - Randal Park | Directions | 2 min |
| Orlando Health Emergency Room - Reunion Village | Directions | 10 min |
| Orlando Health Emergency Room - Waterford Lakes | Directions | 3 min |
| Orlando Health Horizon West Hospital | Directions | 11 min |
| Orlando Health Melbourne Hospital | Directions | 5 min |
| Orlando Health Orlando Regional Medical Center | Directions | 58 min |
| Orlando Health Sebastian River Hospital | Directions | 7 min |
| Orlando Health South Lake Hospital | Directions | 6 min |
| Orlando Health St. Cloud Hospital | Directions | 15 min |